208MO Immune related adverse events and biomarkers after Anbal-cel, novel anti-CD19 CAR-T therapy with dual silencing of PD-1 and TIGIT: Updates from phase I study

Journal article

Peer reviewed

W.S. Kim, S.J. Kim, S.E. Yoon and J. Kim

Annals of oncology, Vol.33, pp.S1516-S1516

11/2022

Metrics

1 Record Views

Title: 208MO Immune related adverse events and biomarkers after Anbal-cel, novel anti-CD19 CAR-T therapy with dual silencing of PD-1 and TIGIT: Updates from phase I study
Creators - without role: W.S. Kim - Samsung Medical Center
S.J. Kim - Sungkyunkwan University
S.E. Yoon - Sungkyunkwan University
J. Kim - Clinical Development, Curocell Inc., Daejeon, Republic of Korea
Publication Details: Annals of oncology, Vol.33, pp.S1516-S1516
Publisher: Elsevier Ltd
Identifiers: 9941481308331
Academic Unit: King Abdullah University of Science & Technology
Language: English
Resource Type: Journal article